Biotech Stocks

biotech stocks 3 of the Best Actively Managed Fidelity Funds
Source: ©iStock.com/AlexRaths
Biotechnology has been one of the fastest advancing industries in the past decade. With new medicine always being synthesized and new ways to fertilize crops, the sector is diverse and prosperous, especially as corporations look for new findings or better efficiency. Subsequently, the biotech stocks are booming and should continue to rise in the future.
Some of the best biotech stocks to buy in 2014 include Amgen (NYSE:AMGN) and Gilead Sciences (NYSE:GILD) although many smaller biotech corporations are on the rise and worth a consideration. Biotech stocks can cure your ailing portfolio and lead you down the road to recovery.

Biotechnology Sector Quote (CIX: MSECTOR5151)

Recent Articles

3 of the Best Actively Managed Fidelity Funds

Fidelity funds offer a broad selection of low-cost, no-load, actively-managed funds. Here are 3 of their best. More 

AMGN Stock: The Dark Underbelly of Amgen Earnings

Amagen reported a stellar-looking earnings report, but a lot of its revenue increases were due to price hikes and not higher adoption. More 

Big Opportunities in Big Pharma

There’s a lot going on in biotech right now, which means there are plenty of opportunities worth looking into. More 

GILD Stock: 2 Big Things You Should Know About Gilead Sciences

Gilead is walloping its biotech peers on its way to cornering the HCV market. With improving sales, income and better cash management, GILD stock is a reliable long-term investment. More 

Short the IBB ETF While Pressure Builds

The price action of the Nasdaq Biotechnology Index (IBB) is flashing warning signs for large-cap biotech. More 

3 Unheralded Biotech ETFs to Buy Now

Want to join biotech stocks on the industry's seemingly never-ending run higher? Consider these lesser-known biotech ETFs. More 

BioMarin (BMRN) Stock Soars, Taking IBB With It

BioMarin (BMRN) stock is soaring on Thursday after promising Phase 2 trial data on a dwarfism drug, vosoritide. The IBB ETF is rallying, too. More 

Can Biotech Stocks Break Out, Or Will They Break Down?

Biotech stocks are a step up from lottery tickets: Fortunes made and lost on the clinical results and regulatory approval. Will they break down or break out? More 

Did Alexion Jump the Shark With Its Synageva Bid? (ALXN, GEVA)

While ALXN seems to have overpaid for GEVA on the surface. However, investors can expect to see the benefits over the long-term. More 

3 Potent Biotech Stocks That Could Pop on Earnings

Harness the volatility of the biotechnology sector by letting stats tell the story. Bank on these three biotech stocks ahead of earnings. More